Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study-Reference-Cited by-同舟云学术

Comparative analysis of single versus tandem autologous stem cell transplantation in patients with multiple myeloma in Korea: the KMM2102 study

Published:2024-04-30 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Jung Jongheon¹,Jung Sung-Hoon²,Lee Je-Jung²,Do Young Rok³,Kang Ka-Won⁴,Lee Jung Lim⁵,Yoon Sung-Soo⁶,Min Chang-Ki⁷,Kang Hye Jin⁸,Lee Ji Hyun⁹,Park Ju-Hyun¹⁰,Kim Kihyun¹¹,Eom Hyeon-Seok¹

Affiliation:

1. National Cancer Center

2. Chonnam National University Hwasun Hospital, Chonnam National University Medical School

3. Keimyung University

4. Korea University College of Medicine

5. Daegu Fatima Hospital Cancer Center

6. Seoul National University Hospital

7. The Catholic University of Korea

8. Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences

9. Dong-A University College of Medicine

10. Dongguk University

11. Sungkyunkwan University School of Medicine, Samsung Medical Center

Abstract

Tandem autologous stem cell transplantation can improve the prognosis of patients with multiple myeloma. However, the precise role of tandem transplantation remains debatable. We evaluated the clinical benefits of tandem transplantation retrospectively. Of the 655 included patients, 117 underwent tandem transplantation; the remaining were assigned to the control group. After a single transplantation, the tandem group achieved a complete remission (CR) rate of 24.8%, which increased to 46.2% after a second transplantation. The tandem group had a significantly longer median PFS than the control group in patients with International Staging System (ISS) III and high-risk cytogenetics (23.1 vs. 14.7 months, p=0.007 for ISS III; 21.7 vs. 13.2 months, p=0.042 for high-risk cytogenetics). The tandem group exhibited significantly superior PFS to the control group (20.3 vs. 12.6 months, p=0.003) among patients who failed to achieve CR after a single transplantation. Tandem transplantation was associated with significantly improved PFS after adjusting for maintenance therapy in patients with ISS III, those with high-risk cytogenetics, and those who did not achieve CR after a single transplantation. Following propensity score matching, the tandem group exhibited significantly longer PFS than the control group (30.3 vs. 13.5 months, p=0.028). Tandem transplantation should be considered in high-risk patients.

Publisher

Research Square Platform LLC

Reference29 articles.

1. 1. Rodriguez-Otero, P., Paiva, B. & San-Miguel. J. F. Roadmap to cure multiple myeloma. Cancer Treat. Rev. 100, 102284. https://doi.org/10.1016/j.ctrv.2021.102284 (2021).

2. 2. Cunningham, D. et al. High-dose melphalan for multiple myeloma: long-term follow-up data. J. Clin. Oncol. 12, 764 − 768. https://doi.org/10.1200/JCO.1994.12.4.764 (1994).

3. 3. Jung, S. H. et al. Frontline therapy for newly diagnosed patients with multiple myeloma. Blood Res. 55, S37–S42 https://doi.org/10.5045/br.2020.S007 (2020).

4. 4. Jung, J., et al. Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. Int. J. Hematol. 112, 84 − 95. https://doi.org/10.1007/s12185-020-02869-y (2020).

5. 5. Attal, M. et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N. Engl. J. Med. 349, 2495–2502. https://doi.org/10.1056/NEJMoa032290 (2003).